NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from Steady Meds? Mail in a sample (US only) and let us test it.

Test my supply
+1 more ↓
78%
Finnrick rating
#150 of 500 ranked vendors
18 of 24 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Steady Meds shows a mixed but improving purity-focus record, with recent Sep/Oct Retatrutide and Tirzepatide identity/purity passes offsetting earlier Retatrutide identity failures and Tirzepatide underfill signals. GHK-Cu is similarly uneven, and missing batch IDs or labels limit confidence despite useful recent volume.

methodology →
vendor intelligence report
Vendor Intelligence Report: Steady Meds

We investigated who actually operates Steady Meds — corporate records, ownership trails, web infrastructure, and how its lab results break down product by product. Read the full report before you order.

22 pages4 risk factors assessed13 Jun 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.05
80%
6
2
Retatrutide
$0.85
79%
11
3
Tirzepatide
$0.32
75%
7
5
CJC-1295
$1.10
-
0
6
Ipamorelin
$0.65
-
0
7
Melanotan II
$0.45
-
0
8
Tesamorelin
$1.45
-
0
9
Vitamin B12
$0.42
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%26 Jan 2026: 78%9 Feb 2026: 79%10 Feb 2026: 80%20 Feb 2026: 82%22 Feb 2026: 86%25 Feb 2026: 84%25 Feb 2026: 84%3 Mar 2026: 84%6 Mar 2026: 84%6 Mar 2026: 85%6 Mar 2026: 85%12 Mar 2026: 85%12 Mar 2026: 86%13 Mar 2026: 84%18 Mar 2026: 85%4 Aug 2026: 83%4 Aug 2026: 82%4 Aug 2026: 80%31 Aug 2026: 81%16 Sep 2026: 81%16 Sep 2026: 81%24 Sep 2026: 79%24 Sep 2026: 78%27 Oct 2026: 78%17 Nov 2026: current 78%78%83%78%Jan 26Nov 26
Peptide testing

Ordered peptides from Steady Meds? Mail in a sample (US only) and let us test it.

Test my supply
Steady Meds test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
27 Oct 2026
Pass
Retatrutide
lab nameView COA
24 Sep 2026
Fail
GHK-Cu
lab nameView COA
24 Sep 2026
Fail
Tirzepatide
lab nameView COA
16 Sep 2026
Pass
Retatrutide
lab nameView COA
16 Sep 2026
Pass
GHK-Cu
lab nameView COA
31 Aug 2026
Pass
Tirzepatide
lab nameView COA
4 Aug 2026
Fail
GHK-Cu
lab nameView COA
4 Aug 2026
Fail
Tirzepatide
lab nameView COA
4 Aug 2026
Fail
Retatrutide
lab nameView COA
18 Mar 2026
Pass
Retatrutide
lab nameView COA
1-10 of 24

About Steady Meds test results from Finnrick

Steady Meds is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 3 peptides and 24 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Steady Meds peptides in this dataset are GHK-Cu (6 tests), Retatrutide (11 tests) and Tirzepatide (7 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 24 recent tests.

Corrections
No corrections.
Peptide testing

Ordered peptides from Steady Meds? Mail in a sample (US only) and let us test it.

Test my supply